Date: 2014-08-20
Type of information: Licensing agreement
Compound: indolcarboxamides including NITD304
Company: Novartis (Switzerland) Global Alliance for TB Drug Development (TB Alliance)
Therapeutic area: Infectious diseases
Type agreement: licensing agreement
Action mechanism: Indolcarboxamides work by blocking MmpL3, a transporter of trehalose monomycolate that is essential for mycobacterial cell wall biosynthesis.
Disease: tuberculosis
Details: * On August 20, 2014, Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD). Under the terms of agreement, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included is a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB. One of these preclinical compounds NITD304, blocks MmpL3, a protein essential for the TB bacterium\'s survival. NITD304 was described last year in a paper published in Science Translational Medicine. (Ujjini H. Manjunatha, Science Translational Medicine, Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. Sci Transl Med 4 December 2013: Vol. 5, Issue 214, p. 214ra168. Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007355)
Financial terms:
Latest news:
